Can Testosterone Help Women's Libido?

What Is HSDD and How Common Is Low Libido in Women?

Hypoactive Sexual Desire Disorder (HSDD) is the most common female sexual dysfunction. It is defined as persistently low or absent sexual desire that causes personal distress, and it cannot be fully explained by another medical or psychiatric condition. The DSM-5 merged HSDD into "Female Sexual Interest/Arousal Disorder" (FSIAD), though the older term persists in most clinical-trial literature.

Population data from the National Health and Social Life Survey found that 22% of women reported low desire, but community-based studies applying the distress criterion narrow the prevalence of true HSDD to roughly 10% of reproductive-age women [1]. A 2008 analysis published in Obstetrics & Gynecology (N=31,581) found that the prevalence of distressing low desire peaked in women aged 45, 64, affecting approximately 12.3% of that group [2]. Rates climb sharply after bilateral oophorectomy, when testosterone and estrogen both drop acutely.

HSDD is not a synonym for "not being in the mood sometimes." Diagnosis requires distress, duration (typically months, not days), and exclusion of relationship conflict, medication effect, or depression as the sole driver [3].

Is Low Libido in Women Hormonal?

Hormones are one significant driver, but rarely the only one. Testosterone, estrogen, progesterone, cortisol, thyroid hormone, and prolactin all influence desire through distinct pathways.

Testosterone acts on androgen receptors throughout the central nervous system and in genital tissue. In the brain, it increases dopaminergic tone in reward circuits and modulates melanocortin pathways that initiate sexual motivation [4]. In the vaginal epithelium, androgens maintain tissue sensitivity and lubrication. Women's serum testosterone peaks in the early-to-mid twenties and declines roughly 50% by the time natural menopause occurs, a gradual slope compared with the sharper estrogen drop at menopause [5].

Estrogen deficiency, the dominant hormonal change of menopause, contributes to genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, and reduced clitoral sensitivity. These physical changes feed back and suppress desire through pain anticipation and negative conditioning [6]. A 2016 JAMA Internal Medicine systematic review found that vaginal estrogen reduced dyspareunia in postmenopausal women with effect sizes (standardized mean difference) ranging from 0.5 to 1.2 across trials [7]. Treating GSM alone sometimes restores satisfying desire without any androgen intervention.

Prolactin excess, thyroid dysfunction, and hypercortisolemia also suppress libido and should be ruled out before attributing low desire solely to testosterone or estrogen deficiency [8].

What Does the Clinical Trial Evidence Say About Testosterone for Women's Libido?

The evidence is strongest for surgically postmenopausal women, meaningful for naturally postmenopausal women, and suggestive but thinner for premenopausal women. Three landmark trials and one large meta-analysis anchor the evidence base.

APHRODITE (2008): The largest placebo-controlled RCT of transdermal testosterone for FSIAD enrolled 814 naturally postmenopausal women not on systemic estrogen and randomized them to a 300 mcg/day testosterone patch or placebo for 52 weeks. Women in the testosterone group gained a mean of 2.1 additional satisfying sexual events (SSEs) per 4 weeks compared with 0.7 in the placebo group, a statistically significant difference (P<0.001) [9]. The number-needed-to-treat for one additional SSE per month was approximately 7.

ADORE (2008): A 24-week RCT of 272 naturally postmenopausal women on oral or transdermal estrogen therapy found the testosterone patch (300 mcg/day) produced a 1.9-SSE increase vs. 0.9 for placebo (P<0.05), with sexual desire domain scores on the Profile of Female Sexual Function improving significantly [10].

Premenopausal data (Davis et al., 2008): A 24-week RCT of 261 premenopausal women with HSDD found that the 300 mcg/day patch increased total satisfying sexual activity compared with placebo (P<0.05), although the effect size was smaller than in postmenopausal cohorts [11].

2019 Global Consensus Position Statement: The International Menopause Society, Endocrine Society, and nine other organizations co-authored a position statement, published simultaneously in multiple journals, concluding that "testosterone therapy for postmenopausal women with HSDD has the best evidence of efficacy for improving sexual function" and that "short-term safety (up to 24 months) is well-established" [12]. The statement specifically endorses physiologic dosing targeting serum testosterone in the premenopausal reference range (15 to 70 ng/dL by most assays).

Goldstat et al. meta-analysis (Lancet, 2003): An early pooled analysis of four RCTs (N=196) showed a significant improvement in well-being, mood, and sexual function with transdermal testosterone versus placebo, with no androgenic side effects at physiologic doses [13].

How Does Testosterone Therapy for Women Work in Practice?

No testosterone product carries FDA approval for women in the United States. Intrinsa (the 300 mcg/day patch studied in APHRODITE) was submitted to the FDA in 2004 but rejected over long-term safety data gaps. The patch remains approved in Europe [14].

Clinicians in the U.S. use three primary approaches:

Compounded transdermal testosterone cream or gel. Pharmacies prepare 0.5 to 2% testosterone cream, typically applied 0.1 to 0.5 mL daily to inner arm or thigh skin, targeting a dose of 150 to 300 mcg/day. Because compounding introduces variability in absorption, serum monitoring at 4 to 8 weeks is standard practice to verify levels stay within the female physiologic range (total testosterone 15 to 70 ng/dL) [15].

Male testosterone gel (e.g., AndroGel 1.62%) used at a fraction of the male dose. A male pump actuation delivers approximately 20.25 mg. Women typically use 1/16th to 1/8th of one actuation, yielding approximately 1.25 to 2.5 mg per day. While cost-effective, dose precision is difficult and transfer risk to partners or children requires careful hand-washing and covered application sites [16].

Pellet implants. Testosterone pellets (25 to 75 mg, depending on body weight and baseline levels) are inserted subcutaneously in the hip or gluteal area every 3 to 6 months. Pellets bypass the liver and provide stable serum levels, but dose correction is impossible once inserted, making supraphysiologic exposure a real concern [17]. The Endocrine Society's 2014 clinical practice guideline cautions that pellets carry the highest risk of supratherapeutic levels among available delivery methods [18].

Oral and injectable testosterone routes are generally avoided for women. Oral methyltestosterone undergoes significant hepatic first-pass metabolism and raises LDL cholesterol. Injections produce peaks and troughs incompatible with the steady-state desired for libido effects.

Does HRT (Estrogen/Progesterone) Increase Libido?

Standard HRT, meaning estrogen with or without progestogen, addresses libido indirectly by correcting estrogen deficiency. It reliably treats GSM and vasomotor symptoms, both of which impair sexual function. When dyspareunia or vaginal dryness is the primary driver of low desire, estrogen therapy alone often restores satisfying sexual activity without any androgen component [19].

Systemic estrogen also increases sex hormone-binding globulin (SHBG), which binds free testosterone and may paradoxically reduce the biologically active fraction of circulating testosterone. This is one reason women who start oral estrogen sometimes report worsening libido despite symptom relief elsewhere. Transdermal estradiol raises SHBG less than oral estradiol because it avoids the hepatic first-pass effect [20].

Tibolone, a synthetic steroid with estrogenic, progestogenic, and androgenic properties, is approved in Europe and Australia for postmenopausal symptoms and has demonstrated significant improvements in sexual desire scores in head-to-head trials against conjugated equine estrogens [21]. It is not FDA-approved in the U.S.

The takeaway for clinical practice: HRT addresses the estrogen-deficiency component of low libido, but if desire remains low after estrogen is optimized and GSM is treated, a separate testosterone assessment is warranted rather than simply escalating HRT dose.

What Are the FDA-Approved Options for Low Libido in Women?

Two drugs carry FDA approval specifically for HSDD, and both target the central nervous system rather than hormones.

Flibanserin (Addyi, 100 mg daily oral): Approved in August 2015 for premenopausal women with generalized acquired HSDD [22]. Flibanserin is a multifunctional serotonin agonist/antagonist that reduces serotonergic inhibition of desire and increases dopaminergic and noradrenergic activity in the prefrontal cortex. In the VIOLET trial (N=1,378), flibanserin increased SSEs by 0.5 per month versus placebo (P<0.001), and reduced distress scores on the Female Sexual Distress Scale [23]. It requires a REMS program because of a significant interaction with alcohol causing hypotension and syncope. Efficacy is modest; roughly 1 in 10 women discontinues within the first month due to dizziness, somnolence, or nausea.

Bremelanotide (Vyleesi, 1.75 mg subcutaneous injection): Approved in June 2019 for premenopausal women with HSDD [24]. Bremelanotide is a melanocortin receptor 4 (MC4R) agonist. It is taken as needed, at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and eight times per month. In the RECONNECT trials (N=1,247), bremelanotide produced statistically significant improvements in desire and distress scores versus placebo; 25% of treated women reported a meaningful improvement in desire versus 17% placebo (P<0.001) [25]. Common side effects include nausea (40%), flushing, and transient blood pressure elevation lasting 8 to 12 hours. A single dose causes a mean systolic BP increase of approximately 6 mmHg.

How Does Vyleesi Feel?

Women in RECONNECT and in post-approval case series describe a fairly consistent sequence of effects beginning 30 to 60 minutes after the subcutaneous injection. A warm flush, often starting in the face and spreading to the chest, is the most common sensation reported [25]. Nausea occurs in roughly 4 in 10 women and is the leading reason for discontinuation. Most who tolerate the first dose report heightened genital sensitivity, increased awareness of arousal cues, and in some cases spontaneous desire within the 1 to 4 hour window of peak plasma concentration [26].

The injection site (abdomen or thigh) may develop transient redness or bruising. Women with darker skin tones have a small risk of focal hyperpigmentation with repeated dosing, particularly on the face or gums, due to MC4R activity in melanocytes [27]. This is rare at approved doses but warrants monitoring.

The experience differs qualitatively from testosterone therapy. Testosterone builds desire slowly over 4 to 12 weeks of daily use by shifting baseline hormonal tone. Vyleesi creates an acute, time-limited window of heightened receptivity. Neither replaces the other; they serve different clinical phenotypes.

What Are the Risks of Testosterone Therapy in Women?

At physiologic doses, the 2019 Global Consensus Position Statement concluded that the short-term safety profile of transdermal testosterone is acceptable, with no significant increase in cardiovascular events, breast cancer, or hepatic abnormalities across trials of up to 24 months [12].

Androgenic side effects, primarily acne and increased facial or body hair (hirsutism), occur in a minority of women, more commonly when serum testosterone drifts above the premenopausal reference range [28]. A 2014 Cochrane review of testosterone for sexual dysfunction in women (N=35 trials, 4,835 participants) found that acne occurred in 6.8% of testosterone-treated women versus 4.5% placebo, and hirsutism in 5.4% versus 3.9%, differences that were statistically significant [29].

Voice deepening and clitoral enlargement are rare at physiologic doses but are reported with supraphysiologic pellet dosing. These effects may be partially irreversible. Routine serum monitoring every 3 to 6 months allows dose correction before virilizing symptoms develop [18].

Long-term cardiovascular and breast cancer data beyond 2 years are limited, which is precisely why the FDA declined to approve Intrinsa. Women with hormone-receptor-positive breast cancer, active liver disease, or unexplained vaginal bleeding are not candidates for testosterone therapy [12].

Who Is a Good Candidate for Testosterone Therapy?

A reasonable candidate is a woman with:

1. Documented distressing low sexual desire (positive score on validated tools such as the FSDS-R or BISF-W).
2. A serum total testosterone in the lower quartile of the premenopausal reference range or below, measured by a high-sensitivity mass spectrometry assay rather than standard immunoassay, which is unreliable at female concentrations [30].
3. Estrogen status optimized or deliberately managed (vaginal estrogen or systemic HRT as appropriate).
4. Depression, medication effects (particularly SSRIs, which blunt desire in up to 40% of users), thyroid dysfunction, and hyperprolactinemia excluded or treated [31].
5. Informed consent covering the off-label status, monitoring requirements, and the limitations of long-term safety data.

The Endocrine Society guideline (2014) advises against empiric testosterone therapy in the absence of distress or without baseline hormone measurement, and explicitly recommends against its use for well-being or energy in the absence of sexual dysfunction as the primary complaint [18].

Monitoring Testosterone Therapy in Women

Baseline labs before starting therapy should include total testosterone (mass spec preferred), free testosterone, SHBG, and a complete metabolic panel. After initiation, serum testosterone is checked at 4 to 8 weeks to confirm levels are within the premenopausal reference range (roughly 15 to 70 ng/dL total testosterone). The Endocrine Society recommends checking levels 3 to 6 months after initiation and every 6 months thereafter [18].

If no clinical response is observed after 6 months of documented physiologic serum levels, testosterone therapy should be discontinued. Continuing indefinitely in the absence of benefit exposes the patient to long-term safety uncertainty without commensurate gain.

Women who conceive while on testosterone therapy should stop immediately. Testosterone is a Category X teratogen with documented virilization of female fetuses [32]. Effective contraception is required for premenopausal women on testosterone.

Sexual function response typically begins at 4 to 8 weeks, with full effect at 12 to 16 weeks. Expecting rapid results and abandoning therapy at 4 weeks is a common error that leads to premature discontinuation before the therapy has had time to act [9].

Serum total testosterone measured at 4 weeks after starting a 300 mcg/day transdermal protocol should land between 15 and 70 ng/dL. Values above 70 ng/dL require dose reduction; values above 150 ng/dL require immediate discontinuation and reassessment.